Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 1,073
- 试验地点
- 1
- 主要终点
- Overall survival from initiation of first systemic anticancer therapy
研究概览
简要总结
Non-interventional study. Data obtained by patient chart reviews.
Retrospective analysis of progression free survival, time to treatment failure and overall survival in a national cohort of patients with metastatic renal cell carcinoma treated in Denmark from 2006-2010 Safety, prognostic factors, predictive factors and co-morbidity assessed by Charlson Comorbidity Index.
The following drugs will be evaluated: Sunitinib, Sorafenib, Temsirolimus, Everolimus, Aldesleukin, Interferon-alfa-2b.
详细描述
No sampling. All eligible patients will be included.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Metastatic renal cell carcinoma
排除标准
- 未提供
结局指标
主要结局
Overall survival from initiation of first systemic anticancer therapy
时间窗: 8 months
Progression free survival from initiation of each systemic anticancer therapy separately
时间窗: 8 months
Time to treatment failure from initiation of each systemic anticancer therapy separately
时间窗: 8 months
次要结局
- Predictive factors(8 months)
- Assessment of prognostic factors and overall survival for patients not receiving systemic therapy(8 months)
- Prognostic factors at baseline associated with efficacy (PFS) of each systemic anticancer therapy and overall survival(8 months)
- Serious Adverse Events: Defined as AEs leading to dose adjustment, treatment interruption/ cessation or death.(8 months)
- Co-morbidity assessed by Charlson Comorbidity Index(8 months)
- Combined PFS and OS on sequential treatment(8 months)
- Assessment of first line immunotherapy´s effect on second line targeted therapy(8 months)